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Background: HIV-associated lipodystrophy syndrome is strongly associated with antiretroviral 
treatment in patients with human immunodeﬁ  ciency virus (HIV). Niacin is thought to affect 
hormone-sensitive lipase (HSL) and lipoprotein lipase (LPL) expression in peripheral and 
intra-abdominal fat (IAF).
Objective: This study investigated the effect of extended-release niacin (ERN) on adipose HSL 
and LPL expression in patients with HIV-associated lipodystrophy syndrome.
Methods: Changes in IAF and peripheral fat content and HSL and LPL expression were exam-
ined in 4 HIV-infected patients recruited from a prospective study treated with ERN. Patients 
underwent limited 8 slice computerized tomography abdominal scans, dual-energy X-ray 
absorptiometry scans, and skin punch biopsies of the mid-thigh at baseline and after 12 weeks 
of ERN. All subjects were on stable highly active antiretroviral therapy prior to and during the 
study. Changes in body habitus were self-reported.
Results: Normalized HSL expression decreased in 3 patients and normalized LPL expression 
increased in all 4 patients when comparing pre- and post-ERN treated samples. All subjects 
showed a decrease in total cholesterol (TC) and triglyceride (TG) levels.
Conclusions: Preliminary analysis suggests ERN may induce changes in HSL and LPL 
expression. This method is a feasible approach to identify changes in adipose RNA expression 
involved with lipolysis.
Keywords: extended-release niacin, HIV, lipodystrophy syndrome, hormone-sensitive lipase 
(HSL), lipoprotein lipase (LPL)
Introduction
The significant reduction in morbidity and mortality associated with human 
immunodeﬁ  ciency virus (HIV) infection seen with the introduction of highly active 
antiretroviral therapy has been accompanied by an increase in adverse effects. One of 
the most common complications is HIV-associated lipodystrophy syndrome, which is 
observed in 30%–60% of patients treated with nucleoside reverse transcriptase inhibi-
tors and/or protease inhibitors (Bodasing and Fox 2003). This syndrome is character-
ized by changes in body fat distribution including an increase in centralized fat in the 
abdomen and cervicodorsal region and a decrease in fat in the face, buttocks, and upper 
and lower limbs (Carr 2003). Although it is not clear whether peripheral lipoatrophy 
poses any health risk, central fat accumulation has been associated with increased risk 
for cardiovascular disease in HIV-infected patients (Behrens et al 2003). These changes 
in body shape are psychologically disturbing to patients, as they are often perceived 
as visible indicators of their HIV status (Fernandes et al 2007). There is presently 
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no standard therapy to treat HIV-associated lipodystrophy 
syndrome (Schambelan et al 2002).
Fessel et al (2002) reported more than a 25% reduction 
of intra-abdominal fat (IAF) in patients with HIV-associated 
lipodystrophy treated with ERN. Niacin has long been 
used in the treatment of dyslipidemias, especially 
hypertriglyceridemia, and has been considered as a treat-
ment for HIV-associated lipodystrophy. Niacin is thought 
to inhibit hormone-sensitive lipase (HSL) and enhance 
lipoprotein lipase (LPL) expression in peripheral fat. 
Conversely, it inhibits LPL and enhances HSL expression 
in intra-abdominal fat (IAF) (Farmer and Gotto 1996). HSL 
is associated with fat mobilization, especially in peripheral 
adipose tissue, while LPL has been linked to visceral fat 
storage (Reynisdottir et al 1997). The objective of this study 
was to identify changes in RNA expression of HSL and LPL 
in relation to clinical and laboratory results and imaging 
measurements. Of interest is the RNA expression of HSL and 
LPL in subcutaneous fat in HIV-infected patients reporting 
lipodystrophy treated with ERN.
Methods
Patients were recruited from a prospective pilot study 
examining the safety and tolerability of ERN on HIV-infected 
individuals with hypertriglyceridemia (Souza et al 2002). 
Patients were eligible if they had self-reported body habitus 
changes conﬁ  rmed by their physician. Patients had to have 
received stable potent antiretroviral therapy for at least 
12 weeks prior to study entry and during the study. The 
only exclusion criterion was pregnancy. Informed consent 
was obtained from all participating patients as per guide-
lines approved by the Committee on Human Studies of the 
University of Hawaii, Manoa. Eligible patients were started 
on ERN at 500 mg once daily at bedtime. The dose of ERN 
was increased by 500 mg every 4 weeks to a maximum 
dose of 1500 mg once daily, which was continued for the 
remainder of the study. Patients underwent limited 8 slice 
computerized tomography (CT) scans of the abdomen to 
estimate the amount of IAF content (Smith et al 2001), 
dual-energy x-ray absorptiometry (DEXA) scans to deter-
mine peripheral fat content, and skin punch biopsies of the 
mid-thigh to determine RNA expression of HSL and LPL at 
baseline and after 12 weeks of ERN therapy. The study was 
completed after 24 weeks of ERN therapy.
A 3-mm skin punch biopsy was performed on the upper 
lateral thigh at entry and 12 weeks after the initiation of ERN 
treatment. Follow-up biopsies at the end of the study were 
obtained adjacent to the initial baseline biopsy. Subcutaneous 
fat tissue was removed from the rest of the biopsy specimen 
using a scalpel and forceps and stored in tissue-freezing 
medium and RNA-Later for nucleic acid extraction at –80 °C. 
RNA was extracted from the fat tissue using the RNeasy 
Lipid Tissue Mini Kit for RNA extraction (Qiagen, Valencia, 
CA, USA) as per the manufacturer’s instructions. The quality 
of the RNA was assessed using UV spectrophotometry and 
reverse transcriptase PCR (RT-PCR) of the cDNA with 
β-globin primers.
cDNA was synthesized from the total cellular RNA 
using the GeneAmp Gold RNA PCR Reagent Kit (Applied 
Biosystems, Foster City, CA, USA) as per the manufacturer’s 
instructions. PCR with β-globin primers (5’-GAA GAG CCA 
AGG ACA GGT AC-3’ and 5’-CAA CTT CAT CCA CGT 
TCA CC-3’) was performed using the following reaction mix: 
nuclease free water, 10 × Taq buffer with MgCl2, 1.25 dNTP, 
10% DMSO, 5’ and 3’ β-globin primers, and Taq polymerase. 
2.0 μL of cDNA was added to the reaction mixture. 1.0 μL 
of peripheral blood mononuclear cell DNA was used as a 
positive control and the negative control consisted of the 
reaction mixture with no added DNA. The reaction condi-
tions were: an initial extension of 94 °C for 5 min, followed 
by 45 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 
1 min, and a ﬁ  nal extension of 72 °C for 3 min in a PE9700 
Thermalcycler (Perkin-Elmer, Norwalk, CT, USA). 10.0 
μL of each reaction was resolved on a 1.5% agarose/1.0% 
NuSieve gel.
PCR ampliﬁ  cation of the cDNA was performed using 
HSL primers (5’-CCC ATC ATC TCC ATC GAC TA-3’ 
and 5’-CTT AAC TCC A-3’) and LPL primers (5’-TAA 
TAC GAC TCA CTA ATA GGG-3’ and 5’-GTG CCA TAC 
A-3’) (Montague et al 1998). The reaction mix contained: 
nuclease free water, 10 × Taq buffer with MgCl2, 1.25 
dNTP, 10% DMSO, 5’ and 3’ HSL and LPL primers, and 
Taq polymerase. The cycling conditions were the same as 
mentioned above, with the exception of an adjusted annealing 
temperature of 57 °C for the HSL primers and 52 °C for the 
LPL primers. PCR products were separated by electropho-
resis on a 1.5%/1.0% agarose/NuSieve gel. For the control 
ampliﬁ  ed product (β-globin) and HSL/LPL products, the gels 
were scanned by a densitometer. The ratio of the measured 
gene (HSL or LPL) to the β-globin was calculated from the 
pre- and post-ERN subcutaneous fat tissues to determine the 
relative changes in HSL and LPL expression.
Results
Four out of 10 patients enrolled in the prospective pilot 
study reported lipodystrophy and were eligible for this study. Biologics: Targets & Therapy 2008:2(4) 919
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The baseline characteristics of the subjects are displayed in 
Table 1. None of the patients had signiﬁ  cant adverse effects 
and all were able to tolerate 1500 mg of ERN (Souza et al 
2002). Viral load prior to initiating therapy was undetectable 
in 3 patients and 205 copies/mL in the 4th patient. CD4+ 
count ranged from 413 to 619 cells/mm3 with a mean of 
502 cells/mm3.
After 12 weeks of ERN therapy, skin biopsies for 
HSL and LPL were performed. No complications from 
the skin biopsies were encountered. RT-PCR analysis 
showed all 8 samples were positive for β-globin. Den-
sitometry readings of the RT-PCR products resulted in 
pixel densities (light units) for each value (β-globin, HSL, 
LPL RNA expression). HSL and LPL RNA expression 
values were then divided by the respective β-globin RNA 
expressions, which normalized each valued as a ratio. 
This approach permitted comparisons between individual 
samples for each patient where each patient was his/her 
own control. Three of the 4 specimens showed a decrease 
in normalized HSL expression when comparing pre- and 
post-ERN treated samples through RT-PCR analysis. An 
increase in normalized LPL expression was observed in 
all 4 specimens. Representative samples of HSL and LPL 
assays are shown in Figure 1.
After 24 weeks of ERN therapy, all patients showed a 
decrease in TC and TG levels as seen in Table 2. The mean 
change in TG level was –385 mg/dL. The mean change in 
TC level was –34 mg/dL. Three of the 4 patients completed 
CT and DEXA scans. The changes in IAF of each patient 
determined by the limited 8 slice abdominal CT scans are 
shown in Figure 2. The mean percent change in IAF at the 
end of the study from baseline was –9.8%. The changes in 
fat content of both legs of each patient determined by DEXA 
are also shown in Figure 2. The mean percent change in leg 
fat from baseline was –14.0%.
Discussion
By controlling hypertriglyceridemia and moderating HSL 
and LPL expression, ERN may potentially decrease IAF 
and increase peripheral fat content. Although the changes in 
enzyme expression were not quantitated, semi quantitative 
analysis shows that LPL expression increased after treatment 
with ERN in all 4 patients, and HSL expression decreased 
in 3 patients. Only 2 patients demonstrated a loss of IAF 
and only 1 patient showed an increase in bilateral leg fat. 
There was no relationship between the change in weight of 
the patients and the change in either visceral or peripheral 
adipose tissue content.
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Table 2 Changes in weight (kg), triglyceride, IAF, bilateral leg fat, and normalized HSL and LPL expression in HIV-infected individuals 
treated with extended-release niacin
Patient ∆ in weight 
(kg)
∆ in triglyceride 
(mg/dL)
∆ in total cholesterol 
(mg/dL)
% ∆ in IAF % ∆ in bilateral 
leg fat
∆ in HSL ∆ in LPL
1  0.46 −407 −69 −10.4 8.4 −0.06 0.26
2 −8.18 −118 −25 −22.7 −16.3 −0.14 0.23
3  1.37 −940 −21 3.7 −34.2  0.08 0.18
4 −1.36 −76 −20 NA NA −0.38 0.82
HSL RT-PCR
L          +          – 1          2
LPL RT-PCR
L          +          – 1          2
L 100 bp DNA ladder 
+ Positive control (non-patient cDNA)
– Negative control
1 Patient sample at entry
2 Patient sample after 12 weeks of ERN therapy
Figure 1 Changes in intra-abdominal fat and peripheral fat content of HIV-infected individuals with lipodystrophy treated with extended-release niacin.
0
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Figure 2 Ethidium bromide stained gel of RT-PCR ampliﬁ  ed samples using HSL (left) and LPL (right) primers.Biologics: Targets & Therapy 2008:2(4) 921
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A larger sample size and a control group may have 
produced a clearer effect. In addition, the skin punch biop-
sies were performed after only 12 weeks of ERN treatment. 
It is possible that 12 weeks were not sufﬁ  cient for ERN to 
exert its full effect on enzyme expression, and therefore on 
lipolytic activity. This group had a selection bias, as patients 
self-reported body changes to be eligible to participate in 
this study, and as a result, may have impacted the results. 
Some of these individuals may have had mild body habitus 
changes and the changes from ERN treatment may have 
been too small to discern. The patients were used as their 
own controls, which does not allow for examination of the 
natural progression of lipodystrophy, and compliance was not 
measured. Furthermore, weight loss due to diet and exercise 
likely had a considerable impact on adipose changes, which 
were not controlled for nor quantiﬁ  ed in this study.
The results of this pilot study show this method can be 
used to determine changes in adipose RNA expression of 
HSL and LPL in HIV-infected individuals treated with ERN. 
A larger deﬁ  nitive study is needed in the future to validate 
the use of ERN in HIV-infected individuals suffering from 
HIV-associated lipodystrophy.
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